{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:51:02Z","timestamp":1781661062348,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s11940-010-0065-x","type":"journal-article","created":{"date-parts":[[2010,3,2]],"date-time":"2010-03-02T00:05:30Z","timestamp":1267488330000},"page":"71-83","source":"Crossref","is-referenced-by-count":68,"title":["Pathogenesis and Treatment of Anti-MAG Neuropathy"],"prefix":"10.1007","volume":"12","author":[{"given":"Marinos C.","family":"Dalakas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,3]]},"reference":[{"key":"65_CR1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1212\/WNL.31.11.1480","volume":"31","author":"JJ Kelly","year":"1981","unstructured":"Kelly JJ, Kyle RA, O\u2019Brien PC, Dyck PJ: The prevalence of monoclonal gammopathy in peripheral neuropathy. Neurology 1981, 31:1480\u20131483.","journal-title":"Neurology"},{"key":"65_CR2","unstructured":"Kelly JJ: Peripheral neuropathies associated with monoclonal gammopathies of undetermined significance. Rev Neurol Dis 2008, 5(2):14\u201322. This nice review provides an up-to-date assessment of the topic."},{"key":"65_CR3","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","volume":"354","author":"RA Kyle","year":"2006","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, et al.: Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006, 354:1362\u20131369.","journal-title":"N Engl J Med"},{"key":"65_CR4","first-page":"301","volume":"3","author":"N Latov","year":"1988","unstructured":"Latov N, Hays A, Sherman WH: Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol 1988, 3:301\u2013332.","journal-title":"Crit Rev Neurobiol"},{"key":"65_CR5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/ana.410100109","volume":"10","author":"MC Dalakas","year":"1981","unstructured":"Dalakas MC, Engel WK: Polyneuropathy and monoclonal gammopathy: studies of 11 patients. Ann Neurol 1981, 10:45\u201352.","journal-title":"Ann Neurol"},{"key":"65_CR6","doi-asserted-by":"crossref","unstructured":"Dalakas MC: Autoimmune peripheral neuropathies. In Clinical Immunology: Principles and Practice, edn 3. Edited by Rich RR, Fleisher TA, Shearer WT, et al.: Philadelphia: Mosby Elsevier; 2008:977\u2013994. This nice review provides an up-to-date assessment on the topic and examines the immunopathology and immunoreactivity of IgM in the paraproteinemic neuropathies.","DOI":"10.1016\/B978-0-323-04404-2.10066-1"},{"key":"65_CR7","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1002\/ana.410370705","volume":"37","author":"N Latov","year":"1995","unstructured":"Latov N: Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies Ann Neurol 1995, 37:S32\u2013S42.","journal-title":"Ann Neurol"},{"issue":"Pt 4","key":"65_CR8","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/brain\/123.4.710","volume":"123","author":"E Nobile-Orazio","year":"2000","unstructured":"Nobile-Orazio E, Meucci N, Baldini L, et al.: Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000, 123(Pt 4):710\u2013717.","journal-title":"Brain"},{"key":"65_CR9","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ana.410190605","volume":"19","author":"MC Dalakas","year":"1986","unstructured":"Dalakas MC: Chronic idiopathic ataxic neuropathy. Ann Neurol 1986, 19:545\u2013554.","journal-title":"Ann Neurol"},{"key":"65_CR10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/archneur.1984.04050180033012","volume":"41","author":"MC Dalakas","year":"1984","unstructured":"Dalakas MC, Teravinen H, Engel WK: Tremor as a feature of chronic relapsing and dysgammaglobulinemic polyneuropathies: incidence and management. Arch Neurol 1984, 41:711\u2013714.","journal-title":"Arch Neurol"},{"key":"65_CR11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ana.410150612","volume":"15","author":"MC Dalakas","year":"1984","unstructured":"Dalakas MC, Papadopoulos NM: Paraproteins in the spinal fluid of patients with paraproteinemic polyneuropathies. Ann Neurol 1984, 15:590\u2013593.","journal-title":"Ann Neurol"},{"issue":"Pt 5","key":"65_CR12","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/brain\/117.5.941","volume":"117","author":"DA Kaku","year":"1994","unstructured":"Kaku DA, England JD, Sumner AJ: Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Brain 1994, 117(Pt 5):941\u2013947.","journal-title":"Brain"},{"key":"65_CR13","doi-asserted-by":"crossref","unstructured":"Lupu VD, Mora CA, Dambrosia J, et al.: Terminal latency index in neuropathy with antibodies against myelin-associated glycoproteins. Muscle Nerve 2007, 35(2):196\u2013202. This useful electrophysiologic study confirms that the terminal latency index is specific for anti-MAG neuropathy and differentiates it from hereditary sensorimotor neuropathy type 1 (HMSN1).","DOI":"10.1002\/mus.20678"},{"issue":"11","key":"65_CR14","doi-asserted-by":"crossref","first-page":"7139","DOI":"10.1073\/pnas.78.11.7139","volume":"78","author":"N Latov","year":"1981","unstructured":"Latov N, Braun PE, Gross RB, et al.: Plasma cell dyscrasia and peripheral neuropathy: identification of the myelin antigens that react with human paraproteins. Proc Natl Acad Sci U S A 1981, 78(11):7139\u20137142.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"65_CR15","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1073\/pnas.81.4.1225","volume":"81","author":"AA Ilyas","year":"1984","unstructured":"Ilyas AA, Quarles RH, McIntosh TD, et al.: IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside. Proc Natl Acad Sci U S A 1984, 81:1225\u20131229.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"65_CR16","doi-asserted-by":"crossref","first-page":"6697","DOI":"10.1073\/pnas.82.19.6697","volume":"82","author":"AA Ilyas","year":"1985","unstructured":"Ilyas AA, Quarles RH, Dalakas MC, Brady RO: Polyneuropathy with monoclonal gammopathy: glycolipids are frequently antigens for IgM paraproteins. Proc Natl Acad Sci U S A 1985, 82:6697\u20136700.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"65_CR17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/ana.410170305","volume":"17","author":"JR Mendell","year":"1985","unstructured":"Mendell JR, Sahenk Z, Whitaker JN, et al.: Polyneuropathy and monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody. Ann Neurol 1985, 17:243\u2013254.","journal-title":"Ann Neurol"},{"key":"65_CR18","doi-asserted-by":"crossref","unstructured":"Kuijf ML, Eurelings M, Tio-Gillen AP, et al.: Detection of anti-MAG antibodies in polyneuropathy associated with IgM monoclonal gammopathy. Neurology 2009, 73(9):688\u2013695. This very useful study confirms with a large number of samples that ELISA is the preferred method of testing for anti-MAG antibodies.","DOI":"10.1212\/WNL.0b013e3181b59a80"},{"key":"65_CR19","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1016\/S0021-9258(18)68935-5","volume":"263","author":"AA Ilyas","year":"1988","unstructured":"Ilyas AA, Li SC, Chou DKH, et al.: Gangliosides GM2, IV4Gal NaC GM1B, and IV4Gal NaC GD1a as antigens for monoclonal immunoglobulin M neuropathy associated with gammopathy. J Biol Chem 1988, 263:4369\u20134373.","journal-title":"J Biol Chem"},{"key":"65_CR20","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/ana.410310621","volume":"31","author":"GC Duane","year":"1992","unstructured":"Duane GC, Farrer RG, Dalakas MC, Quarles RH: Sensory neuropathy associated with monoclonal IgM to GD1b ganglioside. Ann Neurol 1992, 31:683\u2013685.","journal-title":"Ann Neurol"},{"key":"65_CR21","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/ana.410390402","volume":"39","author":"MC Dalakas","year":"1996","unstructured":"Dalakas MC, Quarles RH: Autoimmune ataxic neuropathies (sensory ganglionopathies): Are glycolipids the responsible autoantigens? Ann Neurol 1996, 39:419\u2013422.","journal-title":"Ann Neurol"},{"key":"65_CR22","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1172\/JCI118526","volume":"97","author":"RH Quarles","year":"1996","unstructured":"Quarles RH, Dalakas MC: Do antiganglioside antibodies cause human peripheral neuropathies? J Clin Invest 1996, 97:1136\u20131137.","journal-title":"J Clin Invest"},{"key":"65_CR23","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1056\/NEJM199003083221002","volume":"322","author":"S Monaco","year":"1990","unstructured":"Monaco S, Bonetti B, Ferrari S, et al.: Complement dependent demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. N Engl J Med 1990, 322:844\u2013852.","journal-title":"N Engl J Med"},{"key":"65_CR24","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/ana.20364","volume":"57","author":"R Lombardi","year":"2005","unstructured":"Lombardi R, Erne B, Lauria G, et al.: IgM deposits on skin nerves in antimyelin-associated glycoprotein neuropathy. Ann Neurol 2005, 57:180\u2013187.","journal-title":"Ann Neurol"},{"key":"65_CR25","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/mus.880111111","volume":"11","author":"HJ Willison","year":"1988","unstructured":"Willison HJ, Trapp BD, Bacher JD, et al.: Demyelination induced by intraneural injection of human antimyelin associated glycoprotein antibodies. Muscle Nerve 1988, 11:1169\u20131176.","journal-title":"Muscle Nerve"},{"key":"65_CR26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/ana.410330514","volume":"33","author":"AH Tatum","year":"1993","unstructured":"Tatum AH: Experimental paraprotein neuropathy, demyelination by passive transfer of human IgM anti-MAG. Ann Neurol 1993, 33:502\u2013506.","journal-title":"Ann Neurol"},{"key":"65_CR27","doi-asserted-by":"crossref","unstructured":"Ilyas AA, Gu Y, Dalakas MC, et al.: Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG. J Neuroimmunol 2008, 193(1\u20132):87\u201393. This novel study indicates for the first time that immunization of cats with SGPG produces an ataxic neuronopathy (sensory ganglionopathy), clinically similar to MAG neuropathy.","DOI":"10.1016\/j.jneuroim.2007.10.025"},{"issue":"1\u20132","key":"65_CR28","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0165-5728(96)00025-2","volume":"66","author":"RG Farrer","year":"1996","unstructured":"Farrer RG, Dalakas MC, Quarles RH: Multiple antibodies to nerve glycoconjugates in an unusual patient with neuropathy and monoclonal IgA gammopathy. J Neuroimmunol 1996, 66(1\u20132):71\u201376.","journal-title":"J Neuroimmunol"},{"key":"65_CR29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00415-005-0805-0","volume":"252","author":"E Nobile-Orazio","year":"2005","unstructured":"Nobile-Orazio E: Treatment of dysimmune neuropathies. J Neurol 2005, 252:385\u2013395.","journal-title":"J Neurol"},{"key":"65_CR30","doi-asserted-by":"crossref","unstructured":"Lunn MP, Nobile-Orazio E: Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2006, (2):CD002827.","DOI":"10.1002\/14651858.CD002827.pub2"},{"issue":"1","key":"65_CR31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1085-9489.2006.00059.x","volume":"11","author":"Joint Task Force of EFNS and the PNS","year":"2006","unstructured":"Joint Task Force of EFNS and the PNS: European Federation of Neurological Societies\/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2006, 11(1):9\u201319.","journal-title":"J Peripher Nerv Syst"},{"key":"65_CR32","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1212\/WNL.33.11.1406","volume":"33","author":"MC Dalakas","year":"1983","unstructured":"Dalakas MC, Flaum MA, Rick M, et al.: Treatment of polyneuropathy in Waldenstr\u00f6m\u2019s macroglobulinemia. Role of paraproteinemia and immunological studies. Neurology 1983, 33:1406\u20131410.","journal-title":"Neurology"},{"issue":"1","key":"65_CR33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1212\/01.wnl.0000265055.28218.cc","volume":"69","author":"JM Niermeijer","year":"2007","unstructured":"Niermeijer JM, Eurelings M, van der Linden MW, et al.: Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy. Neurology 2007, 69(1):50\u201359.","journal-title":"Neurology"},{"issue":"5","key":"65_CR34","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/jnnp.66.5.575","volume":"66","author":"HC Wilson","year":"1999","unstructured":"Wilson HC, Lunn MP, Schey S, Hughes RA: Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry 1999, 66(5):575\u2013580.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"65_CR35","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1212\/01.wnl.0000247671.58066.21","volume":"67","author":"JM Niermeijer","year":"2006","unstructured":"Niermeijer JM, Eurelings M, Lokhorst H, et al.: Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy. Neurology 2006, 67(11):2076\u20132079.","journal-title":"Neurology"},{"key":"65_CR36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1212\/WNL.40.2.212","volume":"40","author":"D Cook","year":"1990","unstructured":"Cook D, Dalakas M, Galdi A, et al.: High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 1990, 40:212\u2013214.","journal-title":"Neurology"},{"key":"65_CR37","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ana.410400516","volume":"40","author":"MC Dalakas","year":"1996","unstructured":"Dalakas MC, Quarles RH, Farrer RG, et al.: A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996, 40:792\u2013795.","journal-title":"Ann Neurol"},{"issue":"10","key":"65_CR38","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1007\/s00415-002-0808-z","volume":"249","author":"G Comi","year":"2002","unstructured":"Comi G, Roveri L, Swan A, et al.: A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002, 249(10):1370\u20131377.","journal-title":"J Neurol"},{"key":"65_CR39","doi-asserted-by":"crossref","unstructured":"Attarian S, Boucraut J, Hubert AM, et al.: Chronic ataxic neuropathies associated with anti-GD1b IgM antibodies: response to IVIg therapy. J Neurol Neurosurg Psychiatry 2010, 81(1):61\u201364. This interesting, multicenter (but uncontrolled) study shows some responses to IVIG of the non-MAG\/SGPG but anti-glycolipid antibody-mediated ataxic neuropathy. The main concern is the uncontrolled nature of the study. The encouraging news is that even the ataxic neuropathy, often a ganglionopathy, can be potentially treatable, at least for some patients.","DOI":"10.1136\/jnnp.2009.185736"},{"key":"65_CR40","doi-asserted-by":"crossref","unstructured":"Dalakas MC: B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008, 4(10):557\u2013567. This up-to-date review on B-cell therapies in neurology identifies the various B-cell targets and the new emerging drugs currently being tested in controlled trials in various autoimmune diseases.","DOI":"10.1038\/ncpneuro0901"},{"key":"65_CR41","doi-asserted-by":"crossref","unstructured":"Kosmidis M, Dalakas MC: Rituximab in the treatment of neurological disorders. Ther Adv Neurol Disord 2010 (in press).","DOI":"10.1177\/1756285609356135"},{"issue":"8","key":"65_CR42","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/WNL.52.8.1701","volume":"52","author":"TD Levine","year":"1999","unstructured":"Levine TD, Pestronk A: IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab. Neurology 1999, 52(8):1701\u20131704.","journal-title":"Neurology"},{"key":"65_CR43","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/jnnp.74.4.485","volume":"74","author":"A Pestronk","year":"2003","unstructured":"Pestronk A, Florence J, Miller T, et al.: Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003, 74:485\u2013489.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"65_CR44","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/mus.10359","volume":"27","author":"S Renaud","year":"2003","unstructured":"Renaud S, Gregor M, Fuhr P, et al.: Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003, 27:611\u2013615.","journal-title":"Muscle Nerve"},{"key":"65_CR45","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1212\/01.wnl.0000201193.00382.b3","volume":"66","author":"S Renaud","year":"2006","unstructured":"Renaud S, Fuhr P, Gregor M, et al.: High-dose rituximab and anti-MAG associated polyneuropathy Neurology 2006, 66:742\u2013744.","journal-title":"Neurology"},{"issue":"3","key":"65_CR46","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/mus.20386","volume":"32","author":"L Broglio","year":"2005","unstructured":"Broglio L, Lauria G: Worsening after rituximab treatment in anti-mag neuropathy [letter]. Muscle Nerve 2005, 32(3):378\u2013379.","journal-title":"Muscle Nerve"},{"key":"65_CR47","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1529-8027.2007.00129.x","volume":"12","author":"L Benedetti","year":"2007","unstructured":"Benedetti L, Briani C, Grandis M, et al.: Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin J Periph Nerv Syst 2007, 12:102\u2013107.","journal-title":"J Periph Nerv Syst"},{"key":"65_CR48","doi-asserted-by":"crossref","unstructured":"Benedetti L, Briani C, Franciotta D, et al.: Long term effect of rituximab in anti-MAG polyneuropathy. Neurol 2008, 71(18):1742\u20131744. In an extension of their previous study, this new report provides additional and very useful data on the long-term efficacy of rituximab in anti-MAG neuropathies. Relapses appear to correlate with high anti-MAG titers. Whether these are a marker of disease activity, as proposed, remains to be determined.","DOI":"10.1212\/01.wnl.0000335268.70325.33"},{"key":"65_CR49","doi-asserted-by":"crossref","unstructured":"Dalakas MC, Rakocevic G, Salajegheh M, et al.: Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009, 65(3):286\u2013293. This is the first randomized trial of rituximab in anti-MAG neuropathies and is the largest today in this disease. It presents the means of action of rituximab with immunologic measurements.","DOI":"10.1002\/ana.21577"},{"key":"65_CR50","doi-asserted-by":"crossref","unstructured":"Steck AJ, Czaplinski A, Renaud S: Inflammatory demyelinating neuropathies and neuropathies with monoclonal gammopathies: treatment update. Neurotherapeutics 2008, 5:528\u2013534. This excellent and up-to-date review provides useful and practical guidelines on how best to treat this disease.","DOI":"10.1016\/j.nurt.2008.08.012"},{"issue":"1","key":"65_CR51","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10072-008-0857-x","volume":"29","author":"S Bonavita","year":"2008","unstructured":"Bonavita S, Conforti R, Russo A, et al.: Infratentorial progressive multifocal leukoencephalopathy in a patient treated with fludarabine and rituximab. Neurol Sci 2008, 29(1):37\u201339.","journal-title":"Neurol Sci"},{"key":"65_CR52","unstructured":"FDA Safety Alerts for Human Medical Products: Rituxan (rituximab)\u2014PML. Available at http:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm187791.htm . Accessed January 6, 2010."},{"key":"65_CR53","doi-asserted-by":"crossref","unstructured":"McMaster J, Gibson G, Castro-Prado F, et al.: Neurosurgical treatment of tremor in anti-myelin-associated glycoprotein neuropathy. Neurology 2009, 73(20):1707\u20131708. This is the first study that treats the disabling tremor in patients with anti-MAG neuropathy. Although it presents a single case report, the information is useful to start a trial.","DOI":"10.1212\/WNL.0b013e3181c1de66"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-010-0065-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-010-0065-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-010-0065-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T06:14:54Z","timestamp":1635056094000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-010-0065-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["65"],"URL":"https:\/\/doi.org\/10.1007\/s11940-010-0065-x","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}